Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis

PCR136 A Retrospective Analysis of Real-World Treatment Patterns in Patients over Age 64 with Dry Eye Disease Receiving OTX-101 Ophthalmic Solution 0.09%, Cyclosporine Ophthalmic Emulsion 0.05%, or Lifitegrast Ophthalmic Solution 5%

(2023) P. Karpecki et al.   VALUE IN HEALTH

Prevalence and Incidence of Dry Eye and Meibomian Gland Dysfunction in the United States

(2022) Paul McCann et al.   JAMA Ophthalmology

Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System

(2019) Reza dana et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease

(2019) Damien F. Goldberg et al.   OPHTHALMOLOGY

TFOS DEWS II Report Executive Summary

(2017) Jennifer P. Craig et al.   Ocular Surface

TFOS DEWS II pathophysiology report

(2017) Anthony J. Bron et al.   Ocular Surface

TFOS DEWS II Management and Therapy Report

(2017) Lyndon Jones et al.   Ocular Surface

TFOS DEWS II Definition and Classification Report

(2017) Jennifer P. Craig et al.   Ocular Surface

Lifitegrast for the Treatment of Dry Eye Disease

(2017) Edward J. Holland et al.   OPHTHALMOLOGY

Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease

(2015) Joseph Tauber et al.   OPHTHALMOLOGY

Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease

(2013) John D. Sheppard et al.   OPHTHALMOLOGY

A Phase 2 Randomized, Double-Masked, Placebo-Controlled Study of a Novel Integrin Antagonist (SAR 1118) for the Treatment of Dry Eye

(2012) Charles P. Semba et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Reversibility of Dry Eye Deceleration After Topical Cyclosporine 0.05% Withdrawal

(2011) Sanjay N. Rao   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS